Press Releases


Latest News


Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
Jan 6, 2017 | General Releases

Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
Jan 3, 2017 | General Releases

Adamas Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
Nov 15, 2016 | General Releases

Adamas Reports Third Quarter 2016 Financial Results
Nov 3, 2016 | Financial Releases

Adamas Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
Nov 1, 2016 | General Releases

Adamas Submits New Drug Application to U.S. FDA for ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
Oct 27, 2016 | General Releases

Adamas Pharmaceuticals to Present at the 25th Annual Credit Suisse Healthcare Conference
Oct 24, 2016 | General Releases

Adamas Appoints Michael F. Bigham to Board of Directors
Sep 22, 2016 | General Releases

Allergan and Adamas Announce U.S. Availability of New Dosage Strengths for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
Sep 22, 2016 | General Releases

Adamas Announces Results of EASE LID 3, a Pivotal Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Parkinson's Disease Patients at the 4th World Parkinson Congress
Sep 20, 2016 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10 11